Fermenta Biotech Limited — PPTs, 11-08-2026: Investor Presentation

Here's a summary of the investor presentation for retail investors:

**Business Performance:** Fermenta Biotech reported revenue of INR 126.2 Cr in Q1FY27, down 13% YoY, with human nutrition showing strength, up 24% QoQ to INR 76.5 Cr. India has become a key market, contributing 47% of revenue, up from 35% last year. Growth is expanding beyond Vitamin D3, with segments like Other APIs & Intermediates and Green Chemistry Solutions showing positive YoY growth. Animal nutrition remains a soft spot, with the company prioritizing pricing discipline over volume.

**Growth Drivers or Strategy:** The company is focused on harnessing its "Innovation Chemistry" expertise and scaling advanced manufacturing. Key strategic areas include diversifying its portfolio across vitamins, biocatalysis, and enzymes, and strengthening its global leadership, particularly in Vitamin D3, including a plant-source D3 offering.

**Recent Developments:** Fermenta Biotech received FSSAI approval for VITADEE Green®, a plant-based Vitamin D3, for use in health supplements and food products.

**Key Financial Metrics:** Revenue was INR 126.2 Cr, with Profit after tax at INR 9.5 Cr. Diluted EPS stood at INR 3.34.

**Management Commentary / Outlook:** The company sees strong demand for science-backed nutritional ingredients driven by rising preventive healthcare awareness. Fermenta is well-positioned to capitalize on global and Indian market opportunities. Future growth drivers include plant-source Vitamin D3 and Calcifediol, with dedicated capex for the latter.